Aurinia Pharmaceuticals Future Growth
Future criteria checks 4/6
Aurinia Pharmaceuticals is forecast to grow earnings and revenue by 53.7% and 19.3% per annum respectively while EPS is expected to grow by 53.8% per annum.
Key information
53.7%
Earnings growth rate
53.8%
EPS growth rate
| Biotechs earnings growth | 21.1% |
| Revenue growth rate | 19.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 01 Mar 2024 |
Recent future growth updates
Recent updates
Aurinia Pharmaceuticals: Potential For Significant Upside By Year-End 2024
Apr 18Aurinia Pharma: Cheaper Now, But Buyout Hopes Dashed
Mar 05Analysts Have Been Trimming Their Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Price Target After Its Latest Report
Feb 19
Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) 26% Dip In Price Shows Sentiment Is Matching Revenues
Feb 17Aurinia Pharmaceuticals 2023 Earnings Review: Calling 'Time' In Last Chance Saloon
Feb 15Aurinia Pharmaceuticals: Sales Growth Would Help Buyout Potential
Jan 28We're Interested To See How Aurinia Pharmaceuticals (NASDAQ:AUPH) Uses Its Cash Hoard To Grow
Jan 05Insufficient Growth At Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Hampers Share Price
Dec 18Aurinia Pharmaceuticals (NASDAQ:AUPH) Is In A Strong Position To Grow Its Business
Sep 14Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Low P/S No Reason For Excitement
Jun 11Broker Revenue Forecasts For Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Are Surging Higher
May 09We're Not Worried About Aurinia Pharmaceuticals' (NASDAQ:AUPH) Cash Burn
May 01Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Just Trimmed Their Revenue Forecasts By 26%
Nov 04Aurinia Pharmaceuticals wins European approval of Lupkynis for lupus
Sep 19Aurinia Pharmaceuticals: The Right Play Now
Aug 24Aurinia Pharmaceuticals: Updating My Revenue And Valuation Model
Aug 15Aurinia Pharma Q2 2022 Earnings Preview
Aug 03Aurinia lupus nephritis drug recommended in Europe
Jul 22A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
Jul 04Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval
May 20Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 371 | 129 | 74 | N/A | 4 |
| 12/31/2025 | 288 | 59 | 41 | 97 | 7 |
| 12/31/2024 | 223 | -6 | -5 | 13 | 7 |
| 12/31/2023 | 176 | -78 | -34 | -33 | N/A |
| 9/30/2023 | 159 | -77 | -38 | -37 | N/A |
| 6/30/2023 | 160 | -73 | -40 | -39 | N/A |
| 3/31/2023 | 147 | -97 | -65 | -64 | N/A |
| 12/31/2022 | 134 | -108 | -80 | -80 | N/A |
| 9/30/2022 | 129 | -115 | -110 | -116 | N/A |
| 6/30/2022 | 88 | -157 | -141 | -141 | N/A |
| 3/31/2022 | 66 | -168 | -151 | -151 | N/A |
| 12/31/2021 | 46 | -181 | -159 | -158 | N/A |
| 9/30/2021 | 72 | -156 | -138 | -129 | N/A |
| 6/30/2021 | 58 | -148 | -125 | -117 | N/A |
| 3/31/2021 | 51 | -127 | -109 | -101 | N/A |
| 12/31/2020 | 50 | -103 | -77 | -70 | N/A |
| 9/30/2020 | 0 | -129 | -104 | -98 | N/A |
| 6/30/2020 | 0 | -110 | -83 | -82 | N/A |
| 3/31/2020 | 0 | -102 | -73 | -73 | N/A |
| 12/31/2019 | 0 | -88 | -64 | -64 | N/A |
| 9/30/2019 | 0 | -57 | -52 | -52 | N/A |
| 6/30/2019 | 0 | -52 | -51 | -51 | N/A |
| 3/31/2019 | 0 | -61 | -50 | -50 | N/A |
| 12/31/2018 | 0 | -53 | -52 | -52 | N/A |
| 9/30/2018 | 0 | -53 | -47 | -47 | N/A |
| 6/30/2018 | 0 | -48 | -44 | -44 | N/A |
| 3/31/2018 | 0 | -34 | -46 | -46 | N/A |
| 12/31/2017 | 0 | -71 | -41 | -41 | N/A |
| 9/30/2017 | 0 | -76 | N/A | -36 | N/A |
| 6/30/2017 | 0 | -70 | N/A | -32 | N/A |
| 3/31/2017 | 0 | -71 | N/A | -23 | N/A |
| 12/31/2016 | 0 | -23 | N/A | -19 | N/A |
| 9/30/2016 | 0 | -19 | N/A | -19 | N/A |
| 6/30/2016 | 0 | -17 | N/A | -20 | N/A |
| 3/31/2016 | 0 | -14 | N/A | -19 | N/A |
| 12/31/2015 | 0 | -19 | N/A | -18 | N/A |
| 9/30/2015 | 0 | -21 | N/A | -16 | N/A |
| 6/30/2015 | 0 | -13 | N/A | -15 | N/A |
| 3/31/2015 | 0 | -23 | N/A | -16 | N/A |
| 12/31/2014 | 0 | -19 | N/A | -17 | N/A |
| 9/30/2014 | 1 | -15 | N/A | -16 | N/A |
| 6/30/2014 | 1 | -17 | N/A | -14 | N/A |
| 3/31/2014 | 1 | -7 | N/A | -10 | N/A |
| 12/31/2013 | 1 | -3 | N/A | -5 | N/A |
| 9/30/2013 | 0 | -6 | N/A | -3 | N/A |
| 6/30/2013 | 0 | -8 | N/A | -2 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AUPH is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: AUPH is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: AUPH is expected to become profitable in the next 3 years.
Revenue vs Market: AUPH's revenue (19.3% per year) is forecast to grow faster than the US market (7.9% per year).
High Growth Revenue: AUPH's revenue (19.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AUPH's Return on Equity is forecast to be high in 3 years time